Medican Enterprises Inc
OTC:MDCN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (12.1), the stock would be worth $-0 (5 067% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.2 | $0 |
0%
|
| Industry Average | 12.1 | $-0 |
-5 067%
|
| Country Average | 19.6 | $-0.01 |
-8 158%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
M
|
Medican Enterprises Inc
OTC:MDCN
|
46.5k USD | -0.2 | -0 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 30.4 | 42.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 21.2 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.1 | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 22.8 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 15.9 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 11.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.4 | 10.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 10.1 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.4B USD | 8.8 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Medican Enterprises Inc
Glance View
Medican Enterprises, Inc. is a bio-pharmaceutical company, which engages in the production, cultivation, and wholesale distribution of cannabis related products. The company is headquartered in Las Vegas, Nevada and currently employs 3 full-time employees. The company went IPO on 2000-05-22. The firm is engaged in wholesale medical marijuana production, cultivation, and wholesale distribution of cannabis related products. Through joint ventures with development partners all over Canada and the United States, the Company builds and operates medical marijuana cultivation and research centers. The firm focuses on cultivating approximately five strains of cannabis, including High tetrahydrocannabinol (THC)/Low Cannabidiol (CBD), Medium THC/Low CBD, Medium THC/Medium CBD and Low TCH/High CBD. The firm provides strategic planning, valuation, project debt and corporate finance solutions to its joint venture partners in order to capitalize on the growing medical marijuana market and fund multiple facilities. The firm's subsidiary, Medican Systems Inc., is a licensed producer of medical marijuana under the new program marijuana for medical purposes regulation.
